Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies. (EPIDEX)

Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies : a Multicentre Randomized Controlled Trial

The combined administration of high dose of oral betamethasone and nebulization of adrenaline seems to be an attractive therapeutic alternative for reducing the rate of hospitalization for acute bronchiolitis treated in the emergency department. However, it is essential to confirm the trend previously observed with this treatment before using it in current practice.

Study Overview

• Status: Terminated
• Conditions: Children; Bronchiolitis
• Intervention / Treatment: Drug: 0.9% saline solution; Drug: oral betamethasone placebo; Drug: adrenaline; Drug: oral betamethasone

Detailed Description

Rationale: In infancy, bronchiolitis is the most common acute infection of the lower respiratory tract and is most often caused by the respiratory syncytial virus (RSV). The current treatment of bronchiolitis is controversial. Although meta-analysis of nebulized bronchodilators or corticosteroids treatments failed to show any consistent benefits on admission rate, they remain widely used in pediatric emergency wards. A recent randomized, double-blind, placebo-controlled, clinical trial with a factorial design was conducted to determine whether treatment with nebulized epinephrine, a short course of high dose of oral Betamethasone, or both, resulted in a clinically important decrease in hospital admissions among infants with bronchiolitis who were seen in the emergency department. This study showed that infants in the epinephrine-betamethasone group were significantly less likely than those in the placebo group to be admitted by day 7 (relative risk, 0.65; 95% confidence interval, 0.45 to 0.95, P = 0.02). However, after adjustment for multiple comparisons, this result became insignificant (P = 0.07). This synergistic interaction was not anticipated but gave hope that the association nebulized epinephrine - short course of oral high dose of betamethasone might reduce the risk of hospitalization for infants who consulted pediatric emergencies for a moderate to severe acute bronchiolitis. It is therefore required to conduct a trial dedicated to this evaluation in the French population.

Hypothesis: using Epinephrine-Betamethasone allows to reduce the rate of hospitalization of mild-to-severe acute viral bronchiolitis seen in pediatric emergency departments.

• Study Type: Interventional
• Enrollment (Actual): 195
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• France
  • Clamart, France, 92141
    • AP-HP, Antoine Béclère Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 2 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Infants aged 6 weeks to 12 months admitted in paediatric emergency
• First episode of acute bronchiolitis defined as: expiratory dyspnea with breath slowing and/or sibilants and/or crackles preceded by (or associated with) a nasopharyngitis more or less febrile
• Respiratory distress assessment index score (RDAI) of 4 to 15 after a nasopharyngeal clearance
• Agreement of at least one of the parents for his child to participate in biomedical research
• Affiliation to social security (beneficiary or entitled), except beneficiary of State medical help

Exclusion Criteria:

• Prematurity (less than 37 weeks of gestation)
• Antecedent of invasive respiratory ventilation during neonatal period
• Antecedent of lung or chronic cardiac pathology of wich rhythm disorder, acute obstructive cardiomyopathy and coronary insufficiency
• Immune deficiency
• Active viral infection (hepatitis, zona, herpes, varicella, HIV)
• Proven or suspected tuberculosis
• Exposure to varicella during 15 days before inclusion
• Severe distress (defined as one of following signs: a pulse rate >200/min, respiratory rate >80/min, RDAI score >15, neurological disorders)
• Nebulization (aerosol spray) of Salbutamol or other bronchodilator treatment during the 24 hours before the inclusion
• Inhalation (spray) of Salbutamol during the preceding 24 hours
• Oral or inhaled corticosteroids during the preceding 2 weeks
• Previous episode of wheezing or ascertained diagnosis of asthma
• Hypersensitivity to one of the constituting of oral betamethasone
• Vaccination by living vaccine during the preceding 2 weeks

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: 0.9% saline solution - oral betamethasone placebo; Control arm: 0.9% saline solution - oral betamethasone placebo	Drug: 0.9% saline solution; Placebo: Nebulized 0.9% saline solution; Drug: oral betamethasone placebo; placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
Experimental: adrenaline - oral betamethasone; Experimental arm : adrenaline and betamethasone	Drug: adrenaline; Catecholamine nebulized adrenaline (3 ml of 1:1000 solution); Drug: oral betamethasone; Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hospital admission up to 7 days after enrollment, which occurred during the visit in the emergency department	determine whether treatment with nebulized adrenaline (3 ml of 1:1000 solution) and a short course of oral dexamethasone (1.0 mg/kg) followed by five once-daily doses (0.6 mg/kg) results in a 10% decrease in hospital admissions among infants with mild-to-severe bronchiolitis seen in emergency departments	7 days after enrollment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PICU admission rate following examination in the emergency ward	Estimate and compare the percentages of infants in each group requiring Pediatric Intensive Care Unit (PICU admission).	during the 7 days after enrollment
Length of hospitalization for infants admitted for bronchiolitis in the following 7 days after inclusion	Assess whether experimental treatment reduces healing time and duration of hospitalization of infants included in the study and who have been admitted	7 days after enrollment
Variation of RDAI scores before and after nebulization	Compare clinical scores of respiratory distress before/after treatment	between enrollment and an average of 7 days (the end hospitalization)
Adverse events during the following 7 days after inclusion	Evaluate the tolerance of experimental treatment	7 days after enrollment

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
• Investigators: Principal Investigator: Vincent GAJDOS, AP-HP, Antoine Béclère Hospital

Study record dates

Study Major Dates

• Study Start: October 1, 2015
• Primary Completion (Actual): September 1, 2017
• Study Completion (Anticipated): October 1, 2017

Study Registration Dates

• First Submitted: October 18, 2015
• First Submitted That Met QC Criteria: October 23, 2015
• First Posted (Estimate): October 27, 2015

Study Record Updates

• Last Update Posted (Actual): September 12, 2017
• Last Update Submitted That Met QC Criteria: September 11, 2017
• Last Verified: October 1, 2016

More Information

Terms related to this study

• Keywords: children; bronchiolitis; complication rate; randomized prospective study
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Disease Attributes; Bronchial Diseases; Lung Diseases, Obstructive; Bronchitis; Emergencies; Bronchiolitis; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Adrenergic alpha-Agonists; Adrenergic Agonists; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Adrenergic beta-Agonists; Sympathomimetics; Vasoconstrictor Agents; Mydriatics; Betamethasone; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Betamethasone benzoate; Betamethasone sodium phosphate; Epinephrine; Racepinephrine; Epinephryl borate
• Other Study ID Numbers: P140929; 2015-002477-38 (EudraCT Number)